Thyrocare TechnologiesNSE:THYROCARE -1.87%89 Interest Coverage is 40.17 as of Mar. 2026, which is 50% below its 10-year median of 80.87. GuruFocus rates NSE:THYROCARE with a GF Score™ of 89/100 and a GF Value™ of ₹393.97 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 96 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 82.29% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Thyrocare Technologies's
Operating Income
for the
three
months ended in Mar. 2026 was ₹611 Mil. Thyrocare Technologies's Interest Expense for the
three
months ended in Mar. 2026 was ₹-15 Mil.
Thyrocare Technologies's interest coverage for the quarter that ended in Mar. 2026 was 40.17.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Thyrocare Technologies Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Thyrocare Technologies's Interest Coverage or its related term are showing as below:
NSE:THYROCARE'
s Interest Coverage Range Over the Past 10 Years
Min: 22.07 Med: 80.87 Max: 370.23
Current: 72.66
NSE:THYROCARE's Interest Coverage is ranked better than 82.29% of 96
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs NSE:THYROCARE: 72.66
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thyrocare Technologies Interest Coverage Related Terms
Thyrocare Technologies Interest Coverage Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:THYROCARE vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a Interest Coverage of 40.17 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Thyrocare Technologies and its competitors. This is 50% below median its historical median of 80.87. Over the past decade, Thyrocare Technologies' Interest Coverage has ranged from 22.07 to 370.23. According to the industry distribution chart, Thyrocare Technologies ranks #17 out of 96 companies in the Medical Diagnostics & Research industry, placing it in the top 17.7%.
Is Thyrocare Technologies' Interest Coverage too high?
Thyrocare Technologies' current Interest Coverage of 40.17 is 50% below median its 10-year median of 80.87. Over the past 10 years, this metric has ranged from a low of 22.07 to a high of 370.23. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. Thyrocare Technologies' value of 40.17 is 338.8% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #17 out of 96 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #17 out of 96 companies for Interest Coverage. This places Thyrocare Technologies in the top 18% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 9.16. Thyrocare Technologies' value of 40.17 is 338.8% above this benchmark. Historically, Thyrocare Technologies' own Interest Coverage has ranged from 22.07 to 370.23 over the past decade. While the company's 10-year median is 80.87 vs. the industry median of 9.16, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Interest Coverage of 40.17 is 338.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Interest Coverage is 40.17, which is 50% below median its own 10-year median of 80.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹393.97, compared to a current price of ₹545.20 — trading 38.4% above its estimated fair value. The current Interest Coverage is 40.17, which is 50% below median its 10-year median of 80.87 and 338.8% above the Medical Diagnostics & Research industry median of 9.16. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Interest Coverage is 40.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹545.20 is trading 38.4% above its estimated GF Value™ of ₹393.97.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Interest Coverage: 40.17 (50% below median its 10-year median of 80.87)
GF Value™: ₹393.97 vs. price of ₹545.20 (38.4% above fair value)
Industry Position: 338.8% above the Medical Diagnostics & Research median (#17 of 96)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score
Get the complete analysis for NSE:THYROCARE
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
